Skip to main content
. Author manuscript; available in PMC: 2017 Nov 21.
Published in final edited form as: ACS Nano. 2017 Oct 12;11(10):10135–10146. doi: 10.1021/acsnano.7b04717

Figure 5.

Figure 5

B16F10 subcutaneous tumor growth in (a, b) immune-competent C57BL/6 (n = 10 per group) and (c, d) immune-compromised Balb/c nude mice (n = 6 per group). 1.5 mg siRNA per kg, q3d × 5. mean ± s.d. (a) Tumor volume change in C57BL/6 mice. *: p < 0.05; #: p < 0.0001 vs. PBS group at each day by Dunnett’s test. (b) Tumor specific growth rate in C57BL/6 mice. ****: p < 0.0001 by Tukey’s multiple comparisons test. (c) Tumor volume change in Balb/c nude mice. *: p < 0.05; ***: p < 0.001; #: p < 0.0001 vs. PBS group at each day by Dunnett’s test. (d) Tumor specific growth rate in Balb/c nude mice. *: p < 0.05 by Tukey’s multiple comparisons test.